All lobbying filings

Arnold & Porter Kaye Scholer LLP

Arnold & Porter Kaye Scholer LLP filed a Q2 report for Novo Nordisk, Inc. on July 17, 2026, reporting $70,000 in lobbying income.

Lobbying for Novo Nordisk, Inc. · Pharmaceutical company.

As filed: ARNOLD & PORTER KAYE SCHOLER LLP for NOVO NORDISK, INC.

All filings by Arnold & Porter Kaye Scholer LLP · Everything Novo Nordisk, Inc. has reported

Filing · LD-2 quarterly report Q2 report

Reporting period

2nd Quarter 2026

Apr 1 - June 30 · Posted Jul 17, 2026

Income

$70,000

What the client paid this registrant for the period.

Client based in

New Jersey

Official filing document

Government bodies contacted 2

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 4

Health Issues

Issues related to the clinical and overall benefit of anti-obesity medications. Issues related to insulin pricing/affordability. Issues related to general compounding.

Medicare/Medicaid

Issues related to CMS coverage of anti-obesity medications, including the Treat and Reduce Obesity Act of 2025 (H.R. 4231 / S. 1973).

Consumer Issues/Safety/Products

Issues related to general compounding.

Pharmacy

Issues related to general compounding.

Bills named in this filing 2

H.R. 4231
Treat and Reduce Obesity Act of 2025
S. 1973
Treat and Reduce Obesity Act of 2025

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.